SNTI Stock Overview
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Senti Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.27 |
| Beta | 2.97 |
| 1 Month Change | 5.56% |
| 3 Month Change | -14.75% |
| 1 Year Change | -62.63% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.29% |
Recent News & Updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13Shareholder Returns
| SNTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 1.3% | 3.3% |
| 1Y | -62.6% | 3.0% | 25.0% |
Return vs Industry: SNTI underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: SNTI underperformed the US Market which returned 25% over the past year.
Price Volatility
| SNTI volatility | |
|---|---|
| SNTI Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNTI's share price has been volatile over the past 3 months.
Volatility Over Time: SNTI's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 48 | Tim Lu | www.sentibio.com |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Senti Biosciences, Inc. Fundamentals Summary
| SNTI fundamental statistics | |
|---|---|
| Market cap | US$18.29m |
| Earnings (TTM) | -US$83.41m |
| Revenue (TTM) | US$2.56m |
6.6x
P/S Ratio-0.2x
P/E RatioIs SNTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNTI income statement (TTM) | |
|---|---|
| Revenue | US$2.56m |
| Cost of Revenue | US$32.15m |
| Gross Profit | -US$29.59m |
| Other Expenses | US$53.82m |
| Earnings | -US$83.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | -1,155.37% |
| Net Profit Margin | -3,256.77% |
| Debt/Equity Ratio | 0% |
How did SNTI perform over the long term?
See historical performance and comparison